Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 4/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.46 |
| ▸ | ATR | Q13535 | 8/20 | 0.45 |
| ▸ | ATRIP | Q8WXE1 | 5/20 | 0.45 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.41 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | RAF1 | P04049 | 2/20 | 0.40 |
| ▸ | BRAF | P15056 | 2/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20798021 | 1.00 | PIK3CD (0.46) | PIK3CDPIK3CAATRATRIPPIK3C3 | |
| SCHEMBL30629327 | 0.90 | HRH4 (0.51) | PIK3CDPIK3CAATRATRIPPIK3C3 | |
| SCHEMBL20797856 | 0.90 | HRH4 (0.51) | PIK3CDPIK3CAATRATRIPPIK3C3 | |
| SCHEMBL20797828 | 0.88 | ATR (0.45) | PIK3CDPIK3CAATRATRIPPIK3C3 | |
| SCHEMBL20797948 | 0.88 | PIK3CA (0.46) | PIK3CDPIK3CAATRATRIPPIK3C3 | |
| SCHEMBL24270151 | 0.87 | ATR (0.45) | PIK3CDPIK3CAATRATRIPPIK3C3 | |
| SCHEMBL24270149 | 0.87 | ATR (0.45) | PIK3CDPIK3CAATRATRIPPIK3C3 | |
| SCHEMBL20798050 | 0.87 | ATR (0.44) | PIK3CDPIK3CAATRATRIPPIK3C3 | |
| SCHEMBL20798055 | 0.86 | PIK3CA (0.44) | PIK3CDPIK3CAATRATRIPPIK3C3 | |
| SCHEMBL30629329 | 0.86 | PIK3CA (0.44) | PIK3CDPIK3CAATRATRIPPIK3C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101809002-B | Morpholino pyrimidine derivatives for use in diseases associated with MTOR kinase and/or PI3K | ASTRAZENECA AB | 2013-03-27 | — | — | CN | disclosed |
| EP-2057140-B1 | MORPHOLINO PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2012-08-08 | — | — | EP | disclosed |
| EP-2057140-B1 | MORPHOLINO PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2012-08-08 | — | — | EP | disclosed |
| EP-2176238-B1 | MORPHOLINO PYRIMIDINE DERIVATIVES USED IN DISEASES LINKED TO MTOR KINASE AND/OR PI3K | ASTRAZENECA AB (SE) | 2012-04-18 | — | — | EP | disclosed |
| EP-2176238-B1 | MORPHOLINO PYRIMIDINE DERIVATIVES USED IN DISEASES LINKED TO MTOR KINASE AND/OR PI3K | ASTRAZENECA AB (SE) | 2012-04-18 | — | — | EP | disclosed |
| US-8138183-B2 | Morpholino pyrimidine derivatives used in diseases linked to mTOR kinase and/or PI3K | ASTRAZENECA AB (SE) | 2012-03-20 | — | — | US | disclosed |
| US-8138183-B2 | Morpholino pyrimidine derivatives used in diseases linked to mTOR kinase and/or PI3K | ASTRAZENECA AB (SE) | 2012-03-20 | — | — | US | disclosed |
| US-8138183-B2 | Morpholino pyrimidine derivatives used in diseases linked to mTOR kinase and/or PI3K | ASTRAZENECA AB (SE) | 2012-03-20 | — | — | US | disclosed |
| US-20100249131-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES USED IN DISEASES LINKED TO MTOR KINASE AND/OR PI3K | ASTRAZENECA AB (SE) | 2010-09-30 | — | — | US | disclosed |
| US-20100249131-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES USED IN DISEASES LINKED TO MTOR KINASE AND/OR PI3K | ASTRAZENECA AB (SE) | 2010-09-30 | — | — | US | disclosed |
| CN-101809002-A | Morpholino pyrimidine derivatives for use in diseases associated with MTOR kinase and/or PI3K | ASTRAZENECA AB | 2010-08-18 | — | — | CN | disclosed |
| US-7750003-B2 | Compounds-943 | ASTRAZENECA AB (SE) | 2010-07-06 | — | — | US | disclosed |
| US-7750003-B2 | Compounds-943 | ASTRAZENECA AB (SE) | 2010-07-06 | — | — | US | disclosed |
| US-7750003-B2 | Compounds-943 | ASTRAZENECA AB (SE) | 2010-07-06 | — | — | US | disclosed |
| CN-101541781-A | Morpholino pyrimidine derivatives for the treatment of proliferative diseases | ASTRAZENECA AB (SE) | 2009-09-23 | — | — | CN | disclosed |
| WO-2009007750-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES USED IN DISEASES LINKED TO MTOR KINASE AND/OR PI3K | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | WO | disclosed |
| US-20080171743-A1 | Transcutaneous immunostimulation | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| US-20080171743-A1 | Transcutaneous immunostimulation | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| US-20080171743-A1 | Transcutaneous immunostimulation | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| WO-2008023159-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171743-A1 | Transcutaneous immunostimulation | NFATC1, TLR9, MTOR | PIK3CD 19/4885PIK3CA 20/4885ATR 1452/4885 |
| US-20100249131-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES USED IN DISEASES LINKED TO MTOR KINASE AND/OR PI3K | PIK3CA, MTOR, PIK3CD | PIK3CD 3/4885PIK3CA 1/4885ATR 1100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.